Study of LP-184 in Patients With Advanced Solid Tumors
← catalyst calendarSponsored by Lantern Pharma Inc. (industry) · LTRN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
64actual
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-09 | actual | When the study began enrolling |
| Primary completion | 2026-07-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- GBM
- TNBC - Triple-Negative Breast Cancer
- NSCLC
- Pancreatic Adenocarcinoma
- DDR Gene Mutation
Interventions
- Drug: LP-184
- Drug: Olaparib
- Drug: Nivolumab & Ipilimumab
Primary outcomes
what the primary-completion date above is the date OFTo evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0
measured 12 months
To determine the MTD of LP-184 based on all available safety (graded by CTCAE v5.0) and PK data.
measured 12 months
To determine the RP2D of LP-184 based on all available safety (graded by CTCAE v5.0), PK, PD and efficacy data
measured 12 months
Publications
- PMID 42581203 — linked by the registry
- PMID 42410111 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LTRN's whole pipeline · Catalyst calendar · Every registered study · What changed